{"id":"apcc","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Thromboembolic events"},{"rate":"null","effect":"Anaphylaxis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"aPCC is a prothrombin complex concentrate that contains all four vitamin K-dependent clotting factors (II, VII, IX, and X). It is used to reverse the anticoagulant effects of warfarin and other vitamin K antagonists in patients with acute bleeding or at high risk of bleeding.","oneSentence":"aPCC is an anticoagulant that works by replacing and controlling the activity of natural anticoagulant proteins in the blood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:11.070Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of anticoagulation due to warfarin or other vitamin K antagonists in patients with acute major bleeding or at high risk of bleeding"},{"name":"Prophylaxis of bleeding in patients with hemophilia A or B undergoing surgery"}]},"trialDetails":[{"nctId":"NCT03569891","phase":"PHASE3","title":"HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-06-27","conditions":"Hemophilia B","enrollment":67},{"nctId":"NCT06096051","phase":"","title":"Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-06-13","conditions":"Intracranial Hemorrhage","enrollment":76},{"nctId":"NCT06379789","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-11","conditions":"Hemophilia B","enrollment":130},{"nctId":"NCT01687608","phase":"PHASE1, PHASE2","title":"Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2013-02-11","conditions":"Hemophilia B","enrollment":30},{"nctId":"NCT05568459","phase":"","title":"A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-01-17","conditions":"Hemophilia B","enrollment":11},{"nctId":"NCT03307980","phase":"PHASE2","title":"Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2017-06-22","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT07094087","phase":"PHASE3","title":"Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-09-15","conditions":"Complex Cardiovascular Surgery With Cardiopulmonary Bypass","enrollment":200},{"nctId":"NCT03861273","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-29","conditions":"Hemophilia B","enrollment":51},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT04590950","phase":"","title":"Dosage and PD Study of Eftrenonacog-alfa","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-18","conditions":"Severe Haemophilia B","enrollment":15},{"nctId":"NCT05568719","phase":"PHASE3","title":"Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-28","conditions":"Hemophilia A, Hemophilia B","enrollment":173},{"nctId":"NCT06008938","phase":"","title":"An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2023-06-15","conditions":"Hemophilia B","enrollment":500},{"nctId":"NCT04563520","phase":"PHASE3","title":"SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT05932914","phase":"","title":"Liver Biopsy Following Gene Therapy For Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Hemophilia A, Hemophilia B","enrollment":8},{"nctId":"NCT07406139","phase":"PHASE4","title":"PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Hemophilia, Inhibitors","enrollment":30},{"nctId":"NCT06429332","phase":"PHASE4","title":"International Care Bundle Evaluation in Cerebral Hemorrhage Research","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-01-07","conditions":"Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage","enrollment":3500},{"nctId":"NCT05145127","phase":"PHASE3","title":"Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-11-17","conditions":"Hemophilia A, Hemophilia B","enrollment":245},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT00979238","phase":"PHASE1","title":"Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-02-22","conditions":"Hemophilia B","enrollment":14},{"nctId":"NCT05156983","phase":"PHASE3","title":"A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-08-24","conditions":"Coagulation Disorder","enrollment":328},{"nctId":"NCT06929260","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2025-05-21","conditions":"Advanced Solid Tumours","enrollment":1},{"nctId":"NCT06399289","phase":"PHASE3","title":"Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2024-07-28","conditions":"Hemophilia B","enrollment":23},{"nctId":"NCT07290634","phase":"","title":"Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion","status":"RECRUITING","sponsor":"Zeliha Alicikus","startDate":"2026-01-30","conditions":"Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma","enrollment":4},{"nctId":"NCT05568888","phase":"PHASE3","title":"Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2023-03-28","conditions":"Traumatic Injury","enrollment":1366},{"nctId":"NCT04867837","phase":"PHASE3","title":"Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor","status":"RECRUITING","sponsor":"Octapharma","startDate":"2021-09-01","conditions":"Acute Major Bleeding","enrollment":260},{"nctId":"NCT03587116","phase":"PHASE3","title":"A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-26","conditions":"Hemophilia B, Hemophilia A","enrollment":212},{"nctId":"NCT05345197","phase":"PHASE2","title":"Emicizumab in Patients With Acquired Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2022-08-31","conditions":"Acquired Hemophilia A","enrollment":51},{"nctId":"NCT04244981","phase":"PHASE4","title":"Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery","status":"RECRUITING","sponsor":"SHI Jia","startDate":"2023-10-25","conditions":"Cardiac Surgical Procedures","enrollment":820},{"nctId":"NCT03901755","phase":"","title":"An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2019-09-12","conditions":"Hemophilia B","enrollment":151},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT05360706","phase":"","title":"Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2021-03-18","conditions":"Hemophilia B","enrollment":9},{"nctId":"NCT05523297","phase":"PHASE3","title":"Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery","status":"COMPLETED","sponsor":"Octapharma","startDate":"2022-11-30","conditions":"Bleeding Cardiac Surgery Patients","enrollment":420},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT05611801","phase":"PHASE3","title":"A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-09","conditions":"Hemophilia A, Hemophilia B","enrollment":100},{"nctId":"NCT06144112","phase":"PHASE4","title":"Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery","status":"NOT_YET_RECRUITING","sponsor":"Konkuk University Medical Center","startDate":"2025-09-01","conditions":"Liver Diseases","enrollment":92},{"nctId":"NCT01154231","phase":"","title":"BeneFIX Drug Use Results Survey [All-Case Surveillance]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10-29","conditions":"Hemophilia B","enrollment":314},{"nctId":"NCT05203679","phase":"PHASE2, PHASE3","title":"Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Xinzhi BioMed Co., Ltd.","startDate":"2021-12-30","conditions":"Hemophilia B","enrollment":32},{"nctId":"NCT03938792","phase":"PHASE3","title":"Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-03-09","conditions":"Hemophilia A, Hemophilia B","enrollment":189},{"nctId":"NCT03598907","phase":"","title":"Point-of-care Management of Coagulopathy in Lung Transplantation","status":"TERMINATED","sponsor":"University Hospital, Motol","startDate":"2018-01-01","conditions":"Lung Transplantation","enrollment":100},{"nctId":"NCT05437211","phase":"NA","title":"A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-06-23","conditions":"Hemophilia","enrollment":24},{"nctId":"NCT06429787","phase":"","title":"Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure","status":"RECRUITING","sponsor":"Octapharma","startDate":"2025-02-14","conditions":"Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk","enrollment":3574},{"nctId":"NCT03341156","phase":"PHASE3","title":"Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2018-07-11","conditions":"Heart Disease End Stage, Heart Failure，Congestive","enrollment":14},{"nctId":"NCT05630651","phase":"NA","title":"The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-19","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT05641610","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-02-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT05709288","phase":"PHASE1","title":"Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-03-23","conditions":"Hemophilia B","enrollment":9},{"nctId":"NCT05152732","phase":"EARLY_PHASE1","title":"Safety and Tolerability of VGB-R04 in Patients With Haemophilia B","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-12-28","conditions":"Hemophilia B","enrollment":3},{"nctId":"NCT04135300","phase":"NA","title":"Gene Therapy for Chinese Hemophilia B","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2019-10-16","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT02561923","phase":"PHASE1","title":"A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-08-27","conditions":"Healthy","enrollment":158},{"nctId":"NCT05281718","phase":"EARLY_PHASE1","title":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2022-08-01","conditions":"Hemophilia A","enrollment":12},{"nctId":"NCT05667805","phase":"PHASE4","title":"Coagulation in Cirrhosis","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2023-01-19","conditions":"Liver Cirrhosis","enrollment":400},{"nctId":"NCT05010707","phase":"PHASE2","title":"Transgender Estradiol Affirming Therapy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-08-02","conditions":"Transgenderism","enrollment":39},{"nctId":"NCT06635707","phase":"","title":"Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-11-01","conditions":"Hypertensive Intracerebral Hemorrhage","enrollment":600},{"nctId":"NCT06627218","phase":"NA","title":"Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-01-01","conditions":"Traumatic Bleeding","enrollment":650},{"nctId":"NCT03055611","phase":"","title":"A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-05-09","conditions":"Haemophilia A, Haemophilia B","enrollment":201},{"nctId":"NCT03655340","phase":"","title":"A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2018-09-12","conditions":"Haemophilia B","enrollment":91},{"nctId":"NCT02937831","phase":"","title":"RIXUBIS Drug Use-Result Survey (Japan)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-16","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT02695160","phase":"PHASE1","title":"Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B","status":"TERMINATED","sponsor":"Sangamo Therapeutics","startDate":"2016-11-15","conditions":"Hemophilia B","enrollment":1},{"nctId":"NCT03489291","phase":"PHASE2","title":"Dose Confirmation Trial of AAV5-hFIXco-Padua","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-07-24","conditions":"Hemophilia B","enrollment":3},{"nctId":"NCT02777424","phase":"PHASE4","title":"CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2016-01-21","conditions":"Intracranial Hemorrhages","enrollment":18},{"nctId":"NCT03855280","phase":"PHASE3","title":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2020-01-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT05127681","phase":"NA","title":"Bone Microarchitecture in Men With Hemophilia","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2023-08-01","conditions":"Severe Hemophilia A, Osteoporosis","enrollment":10},{"nctId":"NCT03921294","phase":"PHASE4","title":"HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor","status":"TERMINATED","sponsor":"Indiana Hemophilia &Thrombosis Center, Inc.","startDate":"2019-05-15","conditions":"Haemophilic Pseudotumour","enrollment":1},{"nctId":"NCT05205863","phase":"PHASE1, PHASE2","title":"Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation","status":"COMPLETED","sponsor":"Prothya Biosolutions","startDate":"2021-11-12","conditions":"Healthy Volunteers","enrollment":69},{"nctId":"NCT04567511","phase":"PHASE4","title":"Hemlibra in Mild Hemophilia A","status":"RECRUITING","sponsor":"Indiana Hemophilia &Thrombosis Center, Inc.","startDate":"2022-07-25","conditions":"Factor VIII Deficiency, Congenital","enrollment":20},{"nctId":"NCT06144099","phase":"PHASE4","title":"Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2024-03-01","conditions":"Prostate Cancer, Spine, Open, Hip Osteoarthritis","enrollment":154},{"nctId":"NCT01561391","phase":"PHASE4","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":36},{"nctId":"NCT04019015","phase":"PHASE2","title":"Prehospital Kcentra for Hemorrhagic Shock","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2021-03-15","conditions":"Trauma Injury","enrollment":166},{"nctId":"NCT05548777","phase":"","title":"Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-15","conditions":"Anticoagulant-related Major Bleed","enrollment":5480},{"nctId":"NCT06144125","phase":"PHASE4","title":"Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2024-03-01","conditions":"Cardiac Valve Disease","enrollment":152},{"nctId":"NCT03064035","phase":"PHASE4","title":"Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2017-04-05","conditions":"Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)","enrollment":79},{"nctId":"NCT02803502","phase":"NA","title":"Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?","status":"UNKNOWN","sponsor":"Brugmann University Hospital","startDate":"2017-01","conditions":"Hemophilia","enrollment":50},{"nctId":"NCT05164471","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B","status":"TERMINATED","sponsor":"Spur Therapeutics","startDate":"2021-12-06","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT03641703","phase":"PHASE1, PHASE2","title":"A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy","status":"TERMINATED","sponsor":"Spur Therapeutics","startDate":"2018-07-10","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT05889754","phase":"","title":"Reliability and Validity of the Turkish Version of the PedHAL","status":"UNKNOWN","sponsor":"Hasan Kalyoncu University","startDate":"2023-05-30","conditions":"Hemophilia, Hemophilia A, Severe, Hemophilia B","enrollment":50},{"nctId":"NCT03075670","phase":"PHASE1","title":"A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-07","conditions":"Congenital Bleeding Disorder, Haemophilia B","enrollment":15},{"nctId":"NCT03533504","phase":"","title":"Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2018-05-09","conditions":"Hemophilia A, Hemophilia B","enrollment":1000},{"nctId":"NCT02740335","phase":"PHASE3","title":"Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-06-08","conditions":"Significant Bleeding Risk","enrollment":208},{"nctId":"NCT03045068","phase":"PHASE4","title":"Platelet Transfusion During Neonatal Open Heart Surgery","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-04-11","conditions":"Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass","enrollment":46},{"nctId":"NCT05738642","phase":"NA","title":"Evaluation of the Efficacy of Early Bunching of a FF-PCC in Patients With Severe Traumatic Hemorrhage","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-01","conditions":"Trauma","enrollment":380},{"nctId":"NCT02764489","phase":"PHASE3","title":"FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2019-02-12","conditions":"Hemophilia A or B With Inhibitors","enrollment":45},{"nctId":"NCT03549871","phase":"PHASE3","title":"A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-07-25","conditions":"Hemophilia","enrollment":80},{"nctId":"NCT00618098","phase":"PHASE3","title":"Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures","status":"COMPLETED","sponsor":"Octapharma","startDate":"2008-05","conditions":"Reversal of Anticoagulant Treatment","enrollment":200},{"nctId":"NCT03809481","phase":"PHASE3","title":"Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban","status":"TERMINATED","sponsor":"Aspen Global Incorporated","startDate":"2019-05-16","conditions":"Heparin-induced Thrombocytopenia","enrollment":7},{"nctId":"NCT04534751","phase":"PHASE4","title":"Factor In the Initial Resuscitation of Severe Trauma 2 Patients","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-04-01","conditions":"Traumatic Hemorrhage, Coagulopathy, Massive Hemorrhage","enrollment":350},{"nctId":"NCT05020483","phase":"PHASE2","title":"FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2021-10","conditions":"Cardiac Disease","enrollment":""},{"nctId":"NCT03369444","phase":"PHASE1, PHASE2","title":"A Factor IX Gene Therapy Study (FIX-GT)","status":"TERMINATED","sponsor":"University College, London","startDate":"2017-12-05","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT03209258","phase":"NA","title":"The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial","status":"COMPLETED","sponsor":"The George Institute for Global Health, China","startDate":"2017-12-12","conditions":"Cerebral Hemorrhage, Stroke, Hypertension","enrollment":7067},{"nctId":"NCT03218722","phase":"PHASE3","title":"Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2017-12-29","conditions":"Shock, Hemorrhagic","enrollment":350},{"nctId":"NCT03565237","phase":"PHASE4","title":"RIXUBIS PMS India (RIXUBIS PMS)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-12-07","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT02053792","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-02-06","conditions":"Hemophilia B","enrollment":97},{"nctId":"NCT04286412","phase":"PHASE4","title":"Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-02-10","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT05441553","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients","status":"UNKNOWN","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","startDate":"2022-07","conditions":"Hemophilia B","enrollment":26},{"nctId":"NCT02396342","phase":"PHASE1, PHASE2","title":"Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-06-10","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT03358836","phase":"","title":"Joint Health Study","status":"COMPLETED","sponsor":"Bloodworks","startDate":"2017-11-15","conditions":"Hemophilia B","enrollment":8},{"nctId":"NCT02557672","phase":"PHASE4","title":"PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-08","conditions":"Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures","enrollment":106},{"nctId":"NCT03417245","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-03-01","conditions":"Hemophilia A, Hemophilia B","enrollment":120},{"nctId":"NCT03417102","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-02-14","conditions":"Hemophilia A, Hemophilia B","enrollment":60},{"nctId":"NCT02234310","phase":"PHASE3","title":"Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2014-11-13","conditions":"Hemophilia B","enrollment":33},{"nctId":"NCT02448680","phase":"PHASE3","title":"A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2015-12-07","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1660,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Factor Eight Inhibitor Bypassing Activity (FEIBA®)"],"phase":"phase_3","status":"active","brandName":"aPCC","genericName":"aPCC","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"aPCC is an anticoagulant that works by replacing and controlling the activity of natural anticoagulant proteins in the blood. Used for Reversal of anticoagulation due to warfarin or other vitamin K antagonists in patients with acute major bleeding or at high risk of bleeding, Prophylaxis of bleeding in patients with hemophilia A or B undergoing surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}